BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 16334161)

  • 21. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
    Reck M; Macha HN; Del Barco S; Cornes P; Vaissière N; Morand M; Riggi M; Abratt R
    Lung Cancer; 2009 Jun; 64(3):319-25. PubMed ID: 19095327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
    Gu Y; Shu Y; Xu Q
    Biomed Pharmacother; 2009 May; 63(4):293-6. PubMed ID: 18848761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.
    Peschel C; Hartmann JT; Schmittel A; Bokemeyer C; Schneller F; Keilholz U; Buchheidt D; Millan S; Izquierdo MA; Hofheinz RD
    Lung Cancer; 2008 Jun; 60(3):374-80. PubMed ID: 18054408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II study of induction chemotherapy followed by concurrent chemoradiotherapy in elderly patients with locally advanced non-small-cell lung cancer.
    Giorgio CG; Pappalardo A; Russo A; Santini D; Di Rosa C; Di Salvo C; Castorina S; Marletta F; Bellissima G; Palermo N; Scuderi C; Bordonaro R
    Anticancer Drugs; 2007 Jul; 18(6):713-9. PubMed ID: 17762402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer.
    Ramalingam S; Perry MC; La Rocca RV; Rinaldi D; Gable PS; Tester WJ; Belani CP
    Cancer; 2008 Aug; 113(3):542-6. PubMed ID: 18512224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.
    Davies AM; Chansky K; Lau DH; Leigh BR; Gaspar LE; Weiss GR; Wozniak AJ; Crowley JJ; Gandara DR;
    J Clin Oncol; 2006 Nov; 24(33):5242-6. PubMed ID: 17114656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
    Chiappori AA; Haura E; Rodriguez FA; Boulware D; Kapoor R; Neuger AM; Lush R; Padilla B; Burton M; Williams C; Simon G; Antonia S; Sullivan DM; Bepler G
    Clin Cancer Res; 2008 Mar; 14(5):1464-9. PubMed ID: 18316570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy.
    Shinohara N; Harabayashi T; Suzuki S; Nagao K; Seki H; Murakumo M; Mitsuhashi K; Demura T; Nagamori S; Matsuyama H; Naito K; Nonomura K
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):402-7. PubMed ID: 16416335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
    Rizvi NA; Riely GJ; Azzoli CG; Miller VA; Ng KK; Fiore J; Chia G; Brower M; Heelan R; Hawkins MJ; Kris MG
    J Clin Oncol; 2008 Feb; 26(4):639-43. PubMed ID: 18235124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Definitive results of a phase I study of a chemotherapy regimen using cisplatin and paclitaxel for non-small cell bronchial cancer].
    Sculier JP; Klastersky J
    Rev Mal Respir; 1995; 12(6):609-14. PubMed ID: 8677355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI.
    Naoki K; Kunikane H; Fujii T; Tsujimura S; Hida N; Okamoto H; Watanabe K
    Jpn J Clin Oncol; 2009 Sep; 39(9):569-75. PubMed ID: 19520687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer.
    Stathopoulos GP; Malamos NA; Aravantinos G; Rigatos S; Christodoulou Ch; Stathopoulos J; Skarlos D
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):123-8. PubMed ID: 17111119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of a biweekly regimen of vinorelbine and cisplatin in advanced non-small cell lung cancer.
    Chen CH; Lin CM; Kao KC; Chang JW; Tsao TC
    Chang Gung Med J; 2007; 30(3):249-55. PubMed ID: 17760276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cisplatin and vinorelbine remains a valid option for the front-line chemotherapy treatment of NSCLC.
    Buccheri G; Ferrigno D; Giordano C;
    Anticancer Res; 2004; 24(6):4227-35. PubMed ID: 15736477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of carboplatin and weekly paclitaxel in advanced non-small cell lung cancer.
    Nakadate M; Yamazaki K; Konishi J; Kinoshita I; Sukoh N; Harada M; Akie K; Ogura S; Ishida T; Munakata M; Dosaka-Akita H; Isobe H; Nishimura M
    Anticancer Res; 2006; 26(5B):3767-72. PubMed ID: 17094399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multi-center phase II trial of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric and gastro-esophageal cancer.
    Sun Q; Liu C; Zhong H; Zhong B; Xu H; Shen W; Wang D
    Jpn J Clin Oncol; 2009 Apr; 39(4):237-43. PubMed ID: 19264768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Results of the phase II EORTC study comparing paclitaxel/cisplatin with teniposide/cisplatin in patients with non-small cell lung cancer. EORTC Lung Cancer Cooperative Group.
    Postmus PE; Giaccone G; Debruyne C; Sahmoud T; Splinter TA; van Zandwijk N
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):10-3. PubMed ID: 8941404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma.
    Sekine I; Nokihara H; Horiike A; Yamamoto N; Kunitoh H; Ohe Y; Tamura T; Kodama T; Saijo N
    Br J Cancer; 2004 Mar; 90(6):1125-8. PubMed ID: 15026789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Paclitaxel and cisplatin combined with etoposide chemotherapy in non-small cell lung cancer with brain metastases].
    Yang QY; Chen LK; Xu GC; Liu JL; Liang Y; Zhang LN
    Ai Zheng; 2004 Nov; 23(11 Suppl):1459-62. PubMed ID: 15566657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Weekly paclitaxel as second/third-line treatment in advanced non-small cell lung cancer patients: efficacy and tolerability.
    Camps C; Caballero C; Blasco A; Safont MJ; Berrocal A; Garde J; Juarez A; Sirera R; Bremnes RM
    Anticancer Res; 2005; 25(6C):4611-4. PubMed ID: 16334151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.